SEC Form 4 · accession 0001264931-15-000019
Immune Therapeutics, Inc. · IMUN
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Seth Elliott
Officer — PRESIDENT/ COO
Period of report
Jan 13, 2015
Accepted (ET)
Jan 15, 2015 · 10:55 am EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001559356
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common StockF1 | Jan 13, 2015 | A | 1,250,000 | $0.00 | A | 1,250,000 | D |
Table II — derivative securities
No Table II lines on this filing.
Explanation of responses
- F1We entered into a Consulting Agreement with The SeVin Group LLC, effective December 18, 2014. The reporting person is a managing member of The SeVin Group LLC. The agreement requires that we issue 1,250,000 restricted shares of our common stock to the reporting person as follows: (i) 625,000 shares, which vested on January 13, 2014; (ii) 375,000 shares, which vest 120 days from the effective date of the agreement; and (iii) 250,000 shares, which vest upon the six-month anniversary of the agreement so long as the agreement has not been previously canceled.